BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-15-0262
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

SKLB-287, a Novel Oral Multikinase Inhibitor of EGFR and VEGFR2, Exhibits Potent Antitumor Activity in LoVo Colorectal Tumor Model

Neoplasma
Cancer Research
2014English

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF

Cancer Research
Cancer ResearchOncology
2018English

Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Cancer Research
Cancer ResearchOncology
2013English

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase With Potent Antimelanoma Activity

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma

Oncotarget
Oncology
2014English

Characterization of a Novel PERK Kinase Inhibitor With Antitumor and Antiangiogenic Activity

Cancer Research
Cancer ResearchOncology
2013English

TAS0728, a Covalent-Binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy